Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer

Summary

The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.

Timeline

Start

2017-09-22

Primary completion

2021-08-23

Completion

2022-03-21

Outcome

Met primary endpoint

paper The primary endpoint was met, as half of the patients were without progression at two months. PMID 37143108 ↗

paper the primary endpoint, progression-free survival (PFS) at two months was met in 17 patients (50%, 95% CI 32-68) PMID 37143108 ↗

Publications

• Jensen LH, Rogatto SR, Lindebjerg J, Havelund B, Abildgaard C, do Canto LM, Vagn-Hansen C, Dam C, Rafaelsen S, Hansen TF. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study. J Exp Clin Cancer Res. 2023 May 5;42(1):115. doi: 10.1186/s13046-023-02683-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	—
Subject	Capecitabine	Small molecule	—	—
Subject	Cetuximab	Monoclonal antibody	—	—
Subject	Irinotecan	Small molecule	—	—
Subject	Oxaliplatin	Small molecule	—	—
Subject	Panitumumab	Monoclonal antibody	—	—
Subject	Regorafenib	Small molecule	—	—
Subject	TAS-102	Small molecule	—	—
Subject	fluorouracil	Small molecule	—	—

Indications